Summary

The Global Non-opioid Pain Treatment Market is valued at approximately USD 42.08 billion in 2023 and is expected to expand at a robust compound annual growth rate (CAGR) of 7.69% over the forecast period from 2024 to 2032. As public health crises surrounding opioid misuse continue to escalate, the healthcare ecosystem has been rigorously shifting towards alternative, safer therapeutic avenues. Non-opioid pain treatments—ranging from NSAIDs to local anesthetics—are fast becoming the backbone of pain management strategies, offering effective relief without the addiction risks associated with opioids. These alternatives are not only addressing chronic and post-operative pain but are also empowering physicians with diverse, targeted solutions across outpatient and inpatient care.
Fueling this paradigm shift are mounting concerns over opioid dependency, coupled with intensified government regulations and awareness campaigns that encourage the prescription of non-addictive medications. Pharmaceutical innovators and biotech companies are funneling investments into novel formulations, extended-release mechanisms, and combination therapies that align with the push for responsible pain care. Innovations in topical agents, transdermal patches, and even injectable anesthetics are offering customizable pain management pathways, enhancing patient compliance and clinical outcomes. At the same time, regulatory fast-tracking and reimbursement expansion in several countries are boosting market accessibility and expediting new product launches.
Non-opioid drugs are being meticulously developed to address both chronic and acute forms of pain across a variety of clinical scenarios. NSAIDs remain a mainstay, widely used for their anti-inflammatory and analgesic properties, particularly in musculoskeletal and arthritic conditions. Local anesthetics are surging in popularity for their precision-targeted nerve blockade capabilities, especially in surgical and dental procedures. These treatments are being administered through oral, intravenous, topical, and other delivery systems, offering clinicians flexibility in aligning treatments with patient-specific conditions and tolerability profiles.
North America currently dominates the global non-opioid pain treatment market due to its advanced regulatory framework, high awareness levels, and swift adoption of non-opioid prescriptions post opioid epidemic mandates. Europe trails closely behind, supported by favorable healthcare reimbursement policies and collaborative research initiatives across countries. Meanwhile, the Asia Pacific region is emerging as a lucrative frontier, driven by rising healthcare expenditure, increasing awareness of non-opioid alternatives, and growing burden of chronic diseases. Nations like China, Japan, and India are progressively integrating non-opioid therapeutics into standard medical practice, supported by regional manufacturers and global partnerships.
Major market player included in this report are:
• Teva Pharmaceutical Industries Ltd.
• GlaxoSmithKline plc
• Pfizer Inc.
• Sanofi S.A.
• Bayer AG
• Eli Lilly and Company
• Novartis AG
• Johnson & Johnson
• Abbott Laboratories
• Mallinckrodt Pharmaceuticals
• Endo International plc
• Astellas Pharma Inc.
• Assertio Holdings, Inc.
• Alembic Pharmaceuticals Limited
• Dr. Reddy’s Laboratories Ltd.
The detailed segments and sub-segment of the market are explained below:
By Drug Class:
• NSAIDs
• Local Anesthetics
By Pain Type:
• Chronic Pain
• Post-operative Pain
By Route of Administration:
• Oral
• Parenteral
• Topical
• Others
By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region:
North America
• U.S.
• Canada
Europe
• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe
Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• Rest of Asia Pacific
Latin America
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa
Years considered for the study are as follows:
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032
Key Takeaways:
• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

ページTOPに戻る

Table of Contents

Table of Contents
Chapter 1. Global Non-opioid Pain Treatment Market Executive Summary
1.1. Global Non-opioid Pain Treatment Market Size & Forecast (2022–2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Drug Class
1.3.2. By Pain Type
1.3.3. By Route of Administration
1.3.4. By Distribution Channel
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
Chapter 2. Global Non-opioid Pain Treatment Market Definition and Research Assumptions
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Customer’s Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory Frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Customer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
Chapter 3. Global Non-opioid Pain Treatment Market Dynamics
3.1. Market Drivers
3.1.1. Escalating Opioid Crisis and Dependency Concerns
3.1.2. Regulatory Mandates Favoring Non-addictive Therapies
3.1.3. Growing Burden of Chronic and Post-operative Pain
3.2. Market Challenges
3.2.1. Gastrointestinal and Cardiovascular Risks of NSAIDs
3.2.2. Limited Duration of Local Anesthetic Action
3.2.3. Inconsistent Reimbursement Policies
3.3. Market Opportunities
3.3.1. Development of Extended-release and Combination Products
3.3.2. Expansion of Multimodal Pain Management Protocols
3.3.3. Integration with Digital Pain Monitoring Platforms
Chapter 4. Global Non-opioid Pain Treatment Market Industry Analysis
4.1. Porter’s Five Forces Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s Model
4.1.7. Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economic
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top Investment Opportunities
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Non-opioid Pain Treatment Market Size & Forecasts by Drug Class, 2022–2032
5.1. Segment Dashboard
5.2. Revenue Trend Analysis by Drug Class (2022 & 2032)
5.2.1. NSAIDs
5.2.2. Local Anesthetics
Chapter 6. Global Non-opioid Pain Treatment Market Size & Forecasts by Pain Type, 2022–2032
6.1. Segment Dashboard
6.2. Revenue Trend Analysis by Pain Type (2022 & 2032)
6.2.1. Chronic Pain
6.2.2. Post-operative Pain
Chapter 7. Global Non-opioid Pain Treatment Market Size & Forecasts by Route of Administration, 2022–2032
7.1. Segment Dashboard
7.2. Revenue Trend Analysis by Route (2022 & 2032)
7.2.1. Oral
7.2.2. Parenteral
7.2.3. Topical
7.2.4. Others
Chapter 8. Global Non-opioid Pain Treatment Market Size & Forecasts by Distribution Channel, 2022–2032
8.1. Segment Dashboard
8.2. Revenue Trend Analysis by Channel (2022 & 2032)
8.2.1. Hospital Pharmacies
8.2.2. Retail Pharmacies
8.2.3. Online Pharmacies
Chapter 9. Global Non-opioid Pain Treatment Market Size & Forecasts by Region, 2022–2032
9.1. North America Market
9.1.1. U.S.
9.1.1.1. By Drug Class, 2022–2032
9.1.1.2. By Pain Type, 2022–2032
9.1.2. Canada
9.2. Europe Market
9.2.1. UK
9.2.2. Germany
9.2.3. France
9.2.4. Spain
9.2.5. Italy
9.2.6. Rest of Europe
9.3. Asia Pacific Market
9.3.1. China
9.3.2. India
9.3.3. Japan
9.3.4. Australia
9.3.5. South Korea
9.3.6. Rest of APAC
9.4. Latin America Market
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of LATAM
9.5. Middle East & Africa Market
9.5.1. Saudi Arabia
9.5.2. South Africa
9.5.3. Rest of MEA
Chapter 10. Competitive Intelligence
10.1. Key Company SWOT Analysis
10.1.1. Teva Pharmaceutical Industries Ltd.
10.1.2. GlaxoSmithKline plc
10.1.3. Pfizer Inc.
10.2. Top Market Strategies
10.3. Company Profiles
10.3.1. Teva Pharmaceutical Industries Ltd.
10.3.1.1. Key Information
10.3.1.2. Overview
10.3.1.3. Financial (Subject to Data Availability)
10.3.1.4. Product Summary
10.3.1.5. Market Strategies
10.3.2. GlaxoSmithKline plc
10.3.3. Pfizer Inc.
10.3.4. Sanofi S.A.
10.3.5. Bayer AG
10.3.6. Eli Lilly and Company
10.3.7. Novartis AG
10.3.8. Johnson & Johnson
10.3.9. Abbott Laboratories
10.3.10. Mallinckrodt Pharmaceuticals
10.3.11. Endo International plc
10.3.12. Astellas Pharma Inc.
10.3.13. Assertio Holdings, Inc.
10.3.14. Alembic Pharmaceuticals Limited
10.3.15. Dr. Reddy’s Laboratories Ltd.
Chapter 11. Research Process
11.1. Research Process
11.1.1. Data Mining
11.1.2. Analysis
11.1.3. Market Estimation
11.1.4. Validation
11.1.5. Publishing
11.2. Research Attributes